Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.
Also called NCT05844462
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 200 participants
- Registry
-
NCT05844462
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- France
- Registry status
- Recruiting
Technical summary
Registry record NCT05844462. Randomized; triple masking; primary purpose treatment. Start 2024-02-01 (actual); primary completion 2027-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease
- Acronym
- ERASE PH-COPD
- Condition
- Pulmonary Hypertension
- Condition
- Chronic Obstructive Pulmonary Disease
- Intervention (Drug)
- Tadalafil
- Intervention (Drug)
- Placebo
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
Record details
- Record id
cardio:ct-nct05844462- Content hash
3f3be1124786566646dd95aca03e1d0dc13d8ad921320e2a592d05c4db019921